Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 10/31/2025

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications

A phase I study of the CSF1R inhibitor vimseltinib in combination with the PD-L1 inhibitor avelumab in patients with advanced sarcoma.

A phase I study of the CSF1R inhibitor vimseltinib in combination with the PD-L1 inhibitor avelumab in patients with advanced sarcoma.

Journal: ESMO open
Published: May 21, 2025

Vimseltinib (Romvimza) for tenosynovial giant cell tumor.

Vimseltinib (Romvimza) for tenosynovial giant cell tumor.

Journal: The Medical letter on drugs and therapeutics
Published: April 20, 2025

Medical Management of Tenosynovial Giant Cell Tumor.

Medical Management of Tenosynovial Giant Cell Tumor.

Journal: Current oncology reports
Published: April 15, 2025

Vimseltinib: First Approval.

Vimseltinib: First Approval.

Journal: Drugs
Published: April 13, 2025

An evaluation of vimseltinib for treatment of tenosynovial giant cell tumors.

An evaluation of vimseltinib for treatment of tenosynovial giant cell tumors.

Journal: Expert review of anticancer therapy
Published: February 27, 2025

Vimseltinib: A novel colony stimulating factor 1 receptor (CSF1R) inhibitor approved for treatment of tenosynovial giant cell tumors (TGCTs).

Vimseltinib: A novel colony stimulating factor 1 receptor (CSF1R) inhibitor approved for treatment of tenosynovial giant cell tumors (TGCTs).

Journal: Intractable & rare diseases research
Published: February 19, 2025

Emerging treatments for sarcoma: from 2024 onward.

Emerging treatments for sarcoma: from 2024 onward.

Journal: Expert opinion on emerging drugs
Published: January 28, 2025

Vimseltinib versus a placebo in patients with tenosynovial giant cell tumor: a plain language summary of the MOTION phase 3 trial.

Vimseltinib versus a placebo in patients with tenosynovial giant cell tumor: a plain language summary of the MOTION phase 3 trial.

Journal: Future oncology (London, England)
Published: October 08, 2024

Vimseltinib improves outcomes in tenosynovial giant cell tumour.

Vimseltinib improves outcomes in tenosynovial giant cell tumour.

Journal: Nature reviews. Clinical oncology
Published: June 24, 2024

Vimseltinib for tenosynovial giant cell tumour.

Vimseltinib for tenosynovial giant cell tumour.

Journal: Lancet (London, England)
Published: May 04, 2024

Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Journal: Lancet (London, England)
Published: March 29, 2024

CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib.

CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 05, 2024
Showing 1-12 of 17

Last Updated: 10/31/2025